Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Y-mAbs Therapeutics (YMAB) operate in?

Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Y-mAbs Therapeutics Stock (NASDAQ: YMAB) stock price, news, charts, stock research, profile.

Open	$8.27
Close	-
Volume / Avg.	9.89K / 261.38K
Day Range	$8.18 - $8.30
52 Wk Range	6.09 - 20.90
Market Cap	$366.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	27
Short Interest	10.28%
Days to Cover	16.55

Recent News

Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement

Stan Vick

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Vandana Singh

Y-mAbs Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug

Sep

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$8.27
Close	-
Volume / Avg.	9.89K / 261.38K
Day Range	$8.18 - $8.30
52 Wk Range	6.09 - 20.90
Market Cap	$366.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	27
Short Interest	10.28%
Days to Cover	16.55

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Y-mAbs Therapeutics (YMAB) stock?

You can purchase shares of Y-mAbs Therapeutics (NASDAQ:YMAB) through any online brokerage.

View our list of the best stock brokerages

Who are Y-mAbs Therapeutics (YMAB) competitors?

Other companies in Y-mAbs Therapeutics’s space includes: KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN), Voyager Therapeutics (NASDAQ:VYGR), Korro Bio (NASDAQ:KRRO) and Sage Therapeutics (NASDAQ:SAGE).

What is the forecast, or price target, for Y-mAbs Therapeutics (YMAB) stock?

Y-mAbs Therapeutics has a consensus price target of $19.08.

What is the current price for Y-mAbs Therapeutics (YMAB)?

The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $8.18 last updated December 23, 2024 at 9:41 AM EST.

Does Y-mAbs Therapeutics (YMAB) pay a dividend?

There are no upcoming dividends for Y-mAbs Therapeutics.

When is Y-mAbs Therapeutics (NASDAQ:YMAB) reporting earnings?

Y-mAbs Therapeutics’s Q4 earnings are confirmed for Thursday, February 27, 2025.

Is Y-mAbs Therapeutics (YMAB) going to split?

There is no upcoming split for Y-mAbs Therapeutics.

What sector and industry does Y-mAbs Therapeutics (YMAB) operate in?

Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Y-mAbs Therapeutics

Y-mAbs Therapeutics (YMAB) Forecast